Dr. Jim Tananbaum is an entrepreneur in the biotechnology industry. He holds a number of degrees, the first being his Bachelor’s Degree in Math and Computer Science. He graduated in 1989 from Harvard Medical School with his Doctor of Medicine and from MIT with his Master of Science in Information Theory. He is also a graduate of Harvard Business School, earning his MBA in 1991. His medical specialties include genetic epidemiology, clinical immunology, and clinical pharmacology.
It was in January 1991 that Dr. Jim Tananbaum started his professional career, co-founding GelTex. He served as both the Chief Executive Officer of this company, from the beginning of 1991 until the end of 1992, as well as a board member from January 1993 until January 1997. This company created non-systemic drugs and released two drugs with FDA approval, Renzela and Cholestagel. This company was acquired by Genzyme in 1997 for $1.6 billion.
In addition to serving on the board at GelTex, from 1993 to 1997 Dr. Tananbaum was a Partner at Sierra Ventures which was a healthcare services investment firm. Among the companies he invested in were CareSelect and Amerigroup. He left in 1997 in order to co-found Theravance which is a biopharmaceutical company with a diverse set of expertises.
In 2001, Dr. Tananbaum again co-founded a company in the biotechnology industry, Prospect Venture Partners, which was a venture capital firm that focused on investing in startup pharmaceutical companies. He was this company’s Managing Director and successfully led the company for 9 years.
Dr. Tananbaum founded Foresite Capital Management in 2010 and continues to lead the company as its CEO. This company, headquartered in San Francisco, invests in biotechnology firms with late-stage products. The type of companies he invests in includes those that make medical devices, healthcare services, genomics, diagnostics, and biotechnology. His wealth of experience and knowledge has led to him being a very effective investor including his being named to Inc. Magazines top 100 Investors Midas list for 2016.